PwPepwise

Leuprolide

Sex & Libido

a.k.a. Lupron · Eligard

GnRH analog

Leuprolide is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH) that, when given continuously.

§Dosing at a glance

5 protocols · from the research
What it's forDoseHow oftenHowFor how long
Metastatic or advanced prostate cancer (androgen deprivation therapy)7.5 mgEvery 12 wksIntramuscularInjected into a muscle.—
Neoadjuvant androgen deprivation before radical prostatectomy7.5 mg3× dailyOralTaken by mouth.8 mos
Endometriosis-associated pelvic pain3.75 mgDaily—3–6 mos
Uterine fibroids (preoperative treatment)3.75 mgEvery 4 wks—24 wks
Original daily under the skin formulation (historical, largely replaced by depots)1 mgDailySubcutaneousInjected just under the skin, into the fat layer.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Leuprolide is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH) that, when given continuously, suppresses the body's production of sex hormones — testosterone in men and estrogen in women. This hormonal suppression makes it a cornerstone treatment for conditions that are driven by these hormones. In men with advanced prostate cancer, leuprolide reduces testosterone to castrate levels, slowing tumor growth7. When combined with androgen receptor–blocking agents, it further improves survival outcomes1,4,5. In women, leuprolide reduces estrogen and relieves pain associated with endometriosis17 and shrinks uterine fibroids before surgery18. It is also used in fertility treatments to regulate ovulation timing15. One well-established limitation of leuprolide is a temporary testosterone 'flare' that occurs in the first days of treatment in men, as the peptide briefly stimulates hormone production before suppressing it6,19. Long-term use in women carries a meaningful risk of bone density loss, which is substantially reduced when hormonal add-back therapy is used alongside it12,20. Newer agents in the same therapeutic space — including oral GnRH antagonists like relugolix — have demonstrated faster hormone suppression and fewer cardiovascular events compared to leuprolide3, placing leuprolide in an evolving treatment landscape with actively emerging alternatives.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Leuprolide (also known as leuprorelin) is a synthetic nonapeptide analog of endogenous gonadotropin-releasing hormone (GnRH), also referred to as luteinizing hormone-releasing hormone (LHRH). Endogenous GnRH is released from the hypothalamus in a pulsatile fashion, stimulating the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive gonadal sex hormone synthesis. Leuprolide shares structural homology with native GnRH but incorporates amino acid substitutions at positions 6 and 10 that confer resistance to enzymatic degradation and increase receptor binding affinity by several orders of magnitude relative to the native decapeptide.

Upon initial administration, leuprolide acts as a potent GnRH receptor agonist at anterior pituitary gonadotrophs, producing a transient surge in LH, FSH, testosterone (in men), and estradiol (in women) — the clinical 'flare' observed in approximately 82% of leuprolide-treated men19 and documented to cause symptomatic worsening in the first 12 weeks in prostate cancer patients1. With continuous, non-pulsatile stimulation, GnRH receptors undergo desensitization and downregulation through receptor internalization and uncoupling from intracellular signaling cascades (primarily Gq/11-protein coupled phospholipase C pathway and downstream IP3/DAG second messengers). This receptor downregulation leads to a sustained reduction in LH and FSH secretion within 2–4 weeks, resulting in castrate-level testosterone suppression (≤0.5 ng/mL, ≤50 ng/dL) in men6 and profound estrogen suppression in women11,12. This mechanism fundamentally distinguishes GnRH agonists like leuprolide from GnRH antagonists (degarelix, relugolix), which competitively block the receptor immediately without an initial stimulatory phase3,6.

The downstream hormonal suppression achieved by leuprolide exerts its therapeutic effects through hormone deprivation of androgen-sensitive prostate cancer cells, inducing apoptosis and growth arrest7, and through suppression of estrogen-driven endometrial implant proliferation and uterine leiomyoma growth17,18. In the prostate cancer setting, residual androgen signaling via adrenal androgens and intratumoral synthesis can partially overcome medical castration, which explains the additional clinical benefit observed when leuprolide is combined with androgen receptor antagonists such as flutamide1 or enzalutamide4,5, which block androgen receptor-mediated transcription at the nuclear level.

Leuprolide is not orally bioavailable due to rapid gastrointestinal proteolysis and is administered parenterally. Depot microsphere and polymer formulations using poly-lactic-co-glycolic acid (PLGA) allow controlled drug release over 1, 3, or 6-month intervals from intramuscular or subcutaneous injection sites, sustaining therapeutic plasma concentrations without daily injection6,10. Suppression of pituitary-gonadal axis function persists throughout the depot release period, with testosterone recovery beginning weeks to months after cessation, though recovery is substantially faster with GnRH antagonists than with agonists such as leuprolide3. The bone mineral density loss associated with prolonged leuprolide use is mechanistically attributable to estrogen deficiency-driven increases in osteoclast activity and bone resorption11,12,20, and is addressable through concurrent hormonal add-back regimens12,20.

§04Evidence & efficacy

Evidence base
400Studies
234Human
15Animal

Leuprolide has demonstrated efficacy across several hormone-sensitive conditions in well-powered randomized controlled trials.

Prostate cancer — androgen deprivation therapy: Leuprolide achieves testosterone suppression to castrate levels (≤0.5 ng/mL) in 96.4% of patients over 12 months6 and produces objective response rates of 86% in metastatic prostate cancer7, establishing it as an effective medical castration agent. When combined with flutamide, leuprolide improves progression-free survival (16.5 vs. 13.9 months) and overall survival (35.6 vs. 28.3 months) compared to leuprolide alone in advanced prostate cancer1. Combined with enzalutamide, leuprolide plus enzalutamide achieves 87.3% 5-year metastasis-free survival versus 71.4% with leuprolide alone in biochemically recurrent disease (HR 0.42)4, and an 8-year overall survival of 78.9% versus 69.5% with leuprolide alone (HR 0.60)5. Freedom from castration resistance at 5 years reaches 96.6% with the enzalutamide combination versus 67.8% with leuprolide alone9.

Prostate cancer — neoadjuvant use before radical prostatectomy: Neoadjuvant leuprolide plus flutamide reduces positive surgical margin rates (18% vs. 48%)16 and achieves lower PSA nadirs with 8 versus 3 months of treatment10. However, these pathological improvements do not translate into improved 5-year biochemical recurrence-free survival (64.8% vs. 67.6%)14, indicating that short-course neoadjuvant leuprolide does not improve long-term oncological outcomes before radical prostatectomy.

Endometriosis: Depot leuprolide 3.75 mg monthly produces significant reductions in dysmenorrhea, pelvic pain, and pelvic tenderness compared to placebo over 12 weeks17, and achieves pain relief equivalent to dienogest over 24 weeks11 and to DMPA-SC at 6 and 18 months13. Pain relief is sustained for at least 8 months after completing a 12-month course across all treatment groups20.

Uterine fibroids: Leuprolide depot reduces mean uterine volume by 45% at 24 weeks and resolves menorrhagia in 97% of affected patients, compared to a 5% volume increase in placebo-treated patients18. Effects are reversible upon discontinuation.

Controlled ovarian hyperstimulation (IVF): Leuprolide long-protocol achieves clinical pregnancy rates of 38.4% per attempt and retrieves a mean of 14.1 oocytes, outcomes comparable to ganirelix antagonist protocols15.

Comparative position: Leuprolide has been directly surpassed on specific endpoints by newer agents — relugolix achieves superior sustained castration rates (96.7% vs. 88.8%) and faster testosterone suppression3, while degarelix achieves castrate levels by day 3 versus weeks for leuprolide6. Ulipristal acetate achieves faster amenorrhea and fewer hot flashes for fibroid treatment8, and dienogest provides equivalent endometriosis pain relief with markedly better bone safety11.

§05Safety

Leuprolide has an extensively characterized safety profile across multiple indications, derived from decades of large randomized controlled trials.

Testosterone/estrogen flare (GnRH agonist effect): A transient initial surge in testosterone occurs in approximately 82% of men starting leuprolide, as the agonist briefly stimulates gonadotropin release before inducing receptor downregulation19. This flare can temporarily worsen symptoms in men with metastatic prostate cancer during the first 12 weeks of treatment, and co-administration of an antiandrogen such as flutamide substantially mitigates this effect1. GnRH antagonists such as degarelix6 and relugolix3 eliminate this flare entirely.

Hot flashes: Among the most commonly reported side effects across both sexes, leuprolide-induced hypoestrogenism or hypoandrogenism reliably produces vasomotor symptoms. In head-to-head trials for endometriosis, moderate-to-severe hot flashes occurred in 40% of leuprolide-treated women versus 10–11% with ulipristal acetate8 and were more frequent than with dienogest11.

Bone mineral density loss: Prolonged leuprolide use causes clinically significant bone mineral density loss. In endometriosis trials, lumbar spine BMD decreased by 4.04% over 24 weeks11 and by 6.3% over 52 weeks in the monotherapy group12. BMD did not return to pre-treatment baseline even at 24 months post-therapy in the leuprolide-only group20, and loss persisted longer than comparator progestins13. Hormonal add-back therapy with norethindrone acetate effectively preserves bone density without substantially compromising efficacy12,20.

Cardiovascular risk: Long-term androgen deprivation therapy with leuprolide is associated with elevated rates of major adverse cardiovascular events (MACE). In a direct comparison, MACE occurred in 6.2% of leuprolide-treated patients versus 2.9% with relugolix over 48 weeks (HR 0.46)3, highlighting cardiovascular risk as a meaningful consideration in patient selection, particularly for those with pre-existing cardiac conditions.

Injection site reactions: Intramuscular leuprolide depot has substantially fewer local injection site reactions compared to subcutaneous GnRH antagonists — injection site reactions occurred in less than 1% of leuprolide IM patients versus 40% with subcutaneous degarelix6.

Other effects: In neoadjuvant prostate cancer settings, 8 months of leuprolide plus flutamide was associated with more newly reported adverse events (4.5 vs. 2.9 per patient) and higher rates of hot flushes (87% vs. 72%) compared to 3-month treatment, though no additional hemoglobin decline occurred beyond the initial 15% decrease at 3 months10. Flutamide combination was associated with higher rates of diarrhea and anemia in some trials2. Quality of life in combination regimens with enzalutamide showed no substantial between-group differences versus leuprolide alone4.

§06History

Leuprolide emerged from the foundational work on GnRH structure-activity relationships pioneered by Andrew Schally and Roger Guillemin in the early 1970s — research that earned the 1977 Nobel Prize in Physiology or Medicine. Following characterization of the native GnRH decapeptide, medicinal chemistry efforts identified that substitution of D-amino acids at position 6 and deletion of the C-terminal glycinamide residue produced analogs with dramatically enhanced potency and metabolic stability. Leuprolide (leuprorelin) was among the first such superagonist analogs developed, initially as a daily subcutaneous injection formulation.

The first landmark clinical evidence for leuprolide was published in the New England Journal of Medicine in 1984, demonstrating therapeutic equivalence to diethylstilbestrol (DES) for metastatic prostate cancer with a markedly superior tolerability profile, effectively establishing GnRH analogs as the preferred medical castration strategy7. The FDA approved leuprolide for advanced prostate cancer in 1985. Development of biodegradable PLGA depot microsphere formulations in the late 1980s enabled monthly and later quarterly injections, greatly improving patient convenience.

The concept of maximal androgen blockade — combining leuprolide with an antiandrogen — was established through a landmark 1989 NEJM trial demonstrating survival benefit of leuprolide plus flutamide over leuprolide alone1. Indications subsequently expanded to include endometriosis17, uterine fibroids18, precocious puberty, and infertility protocols15. Over four decades of use, leuprolide has accumulated one of the largest randomized controlled trial databases of any therapeutic peptide. The contemporary research landscape is defined by trials evaluating leuprolide as a backbone for combination regimens with next-generation androgen receptor inhibitors4,5,9 and by comparative trials positioning newer GnRH antagonists as successor agents offering faster castration, absence of testosterone flare, and improved cardiovascular safety profiles3,6.

§07References